MBOT Microbot Medical Inc.

Nasdaq www.microbotmedical.com


$ 2.81 nm (nm)    

Monday, 20-Oct-2025 16:59:30 EDT
QQQ $ 612.09 nm (nm)
DIA $ 467.44 nm (nm)
SPY $ 671.90 nm (nm)
TLT $ 91.60 nm (nm)
GLD $ 400.97 $ 14.16 (3.64 %)
$ 2.76
$ 2.86
$ 2.78 x 100
$ 2.82 x 350
$ 2.72 - $ 2.89
$ 0.89 - $ 4.67
1,597,244
na
125.71M
$ 1.44
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-25-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 03-27-2024 12-31-2023 10-K
8 08-14-2023 06-30-2023 10-Q
9 05-17-2023 03-31-2023 10-Q
10 03-31-2023 12-31-2022 10-K
11 11-14-2022 09-30-2022 10-Q
12 08-15-2022 06-30-2022 10-Q
13 05-16-2022 03-31-2022 10-Q
14 03-31-2022 12-31-2021 10-K
15 11-15-2021 09-30-2021 10-Q
16 08-16-2021 06-30-2021 10-Q
17 05-17-2021 03-31-2021 10-Q
18 03-31-2021 12-31-2020 10-K
19 11-16-2020 09-30-2020 10-Q
20 08-14-2020 06-30-2020 10-Q
21 05-15-2020 03-31-2020 10-Q
22 04-14-2020 12-31-2019 10-K
23 11-14-2019 09-30-2019 10-Q
24 08-14-2019 06-30-2019 10-Q
25 05-15-2019 03-31-2019 10-Q
26 04-01-2019 12-31-2018 10-K
27 11-14-2018 09-30-2018 10-Q
28 08-14-2018 06-30-2018 10-Q
29 05-15-2018 03-31-2018 10-Q
30 04-02-2018 12-31-2017 10-K
31 11-14-2017 09-30-2017 10-Q
32 08-14-2017 06-30-2017 10-Q
33 05-15-2017 03-31-2017 10-Q
34 03-21-2017 12-31-2016 10-K
35 11-03-2016 09-30-2016 10-Q
36 08-15-2016 06-30-2016 10-Q
37 05-10-2016 03-31-2016 10-Q
38 03-15-2016 12-31-2015 10-K
39 11-02-2015 09-30-2015 10-Q
40 08-06-2015 06-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 microbot-medical-announces-it-will-exhibit-its-liberty-endovascular-robotic-system-at-symposium-on-clinical-interventional-oncology-in-miami-fl-october-17-19-2025-marking-first-commercial-exhibition-of-the-system-following-its-fda-510k-clearance-in-september-2025

Microbot Medical Inc. (NASDAQ:MBOT), developer and distributer of the innovative LIBERTY® Endovascular Robotic System, today an...

 hc-wainwright--co-reiterates-buy-on-microbot-medical-maintains-12-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Microbot Medical (NASDAQ:MBOT) with a Buy and maintains $12 pr...

 microbot-medical-partners-with-us-based-3pl-company-to-support-commercialization-of-fda-cleared-liberty-system

The Experienced MedTech Logistics Provider Will Help Ensure Effective and Efficient Inventory Management and Customer Support T...

 microbot-medical-announces-that-the-japanese-patent-office-has-granted-the-company-its-first-patent-in-japan-covering-the-core-liberty-system-technology

Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Prote...

 microbot-medical-enters-into-agreements-to-purchase-up-to-13989115-shares-of-common-stock-in-two-tranches-for-up-to-922m-in-gross-proceeds

Microbot Medical Inc. (NASDAQ:MBOT) ("Microbot" or the "Company"), today announced the entry into definitive ag...

 hc-wainwright--co-maintains-buy-on-microbot-medical-raises-price-target-to-12

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Microbot Medical (NASDAQ:MBOT) with a Buy and raises the price ...

 microbot-medical-receives-fda-510k-clearance-for-liberty-robotic-system-targets-q4-2025-commercial-launch

Accelerated Launch Readiness Plans Position Company for Commercialization during Q4 2025The Company's Initial Addressable M...

 us-patent-and-trademark-office-grants-microbot-medical-patent-covering-modular-robotic-surgical-system-includes-base-and-plurality-of-tool-receiver-units-arranged-as-separate-units-and-independently-and-interchangeably-attachable-to-base

 With the Newly Granted IP, the Company's IP Portfolio for the LIBERTY® System now includes 12 patents granted globally and...

 microbot-medical-q2-eps-010-misses-008-estimate

Microbot Medical (NASDAQ:MBOT) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(...

 microbot-medical-announces-it-will-receive-a-non-dilutive-grant-from-the-israel-innovation-authority-in-the-amount-of-630k

Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced it has been ap...

 microbot-medical-added-to-the-russell-microcap-index

Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced that it was ad...

 microbot-medical-expands-commercial-team-ahead-of-anticipated-q3-2025-us-launch-of-liberty-robotic-system-fda-510k-decision-expected-q3-2025

Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY Endovascular Robotic System, today announced the conti...

 hc-wainwright--co-reiterates-buy-on-microbot-medical-maintains-9-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Microbot Medical (NASDAQ:MBOT) with a Buy and maintains $9 pri...

 microbot-medical-presented-for-data-for-the-first-time-from-its-access-pvi-trial-at-the-society-of-interventional-radiology-annual-meeting

Successful robotic navigation was achieved in every case and met the primary endpoint of the studyLIBERTY® showed a 92% reducti...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION